Real-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry
Open Access
- 27 May 2025
- journal article
- research article
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-13
Abstract
Regional variability in the effectiveness and safety of biologic therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA) underscores the need for comprehensive assessment. The aim of this study was to provide real-world evidence of the effectiveness and the safety of biologic for RA, SpA including psoriatic arthritis, in the daily clinical practice. RBSMR registry was a multicenter, cohort study conducted in 10 university departments of rheumatology. The study included RA and SpA patients receiving biotherapy, either as an initiation or ongoing treatment, and investigated for 3 years. The statistical analysis was performed using JAMOVI software (T student test, Mann–Whitney U test, Chi-squared test, Fisher’s exact test, Paired T test and Wilcoxon test). 223 RA and 194 SpA were eligible. After 3 years of follow-up, DAS28 CRP (3.6 ± 1.4 versus 5.8 ± 1.0 at baseline) and ASDAS CRP (1.8[1-2.4] versus 3.5[2.5–4.4] at baseline) significantly improved; 13.8% of RA patients achieved remission based on DAS28 CRP and 20.1% of SpA patients achieved remission based on ASDAS CRP. Overall, 163 and 126 adverse events were reported in RA and SpA patients respectively. Infections were the most frequently reported events with an incidence of 11.8 and 13.4/100 patients-year in RA and SpA respectively. Total incidence rate of tuberculosis was 0.80 patient/100 patients-year. The RBSMR registry provides real-world insights into the effectiveness of biologics in the practice of rheumatology for RA and SpA patients in Morocco. It underscores the critical need for continued vigilance in monitoring and addressing adverse events, with a particular focus on tuberculosis infection.Keywords
This publication has 39 references indexed in Scilit:
- Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort studyRheumatology International, 2022
- Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis RegistryACR Open Rheumatology, 2021
- Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational StudyArthritis Care & Research, 2019
- Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugsJoint Bone Spine, 2018
- Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical PracticeJAMA Internal Medicine, 2017
- Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registersJoint Bone Spine, 2017
- Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III TrialArthritis Care & Research, 2015
- Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartritesRevista Brasileira de Reumatologia, 2015
- Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2015
- The Disease Activity Score and the EULAR Response CriteriaRheumatic Disease Clinics of North America, 2009